Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Takeda Pharmaceutical ADR Rep 0.5 Ord Shs TAK

Healthcare

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer)... see more

Add To Watchlist

Recent & Breaking News (NYSE:TAK)

The Lancet publishes papers from two studies of Takeda's dengue vaccine candidate

Business Wire March 17, 2020

Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

Business Wire March 10, 2020

Takeda Completes Sale of Select OTC and Non-Core Assets to STADA

Business Wire March 4, 2020

Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19

Business Wire March 4, 2020

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

Business Wire March 2, 2020

Takeda Completes Sale of Select OTC and Non-Core Assets to Acino

Business Wire March 2, 2020

Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD

Business Wire March 2, 2020

Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Business Wire February 28, 2020

Healthcare Stocks to Watch

Jonathon Brown February 26, 2020

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

Business Wire February 26, 2020

Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer

Business Wire February 24, 2020

Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

Business Wire February 14, 2020

Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment

Business Wire February 5, 2020

Takeda Canada Announces Significant Investment in First Collaborative Canadian Lung Cancer Research Project with Princess Margaret Cancer Centre

Canada NewsWire February 4, 2020

Takeda Demonstrates Business Momentum, Accelerated Integration Synergies, and Raises FY2019 Guidance Including Positive Reported Operating Profit

Business Wire February 4, 2020

Ontario continues to improve access to treatment for children and adolescents living with ADHD who are prescribed INTUNIV XR®*

Canada NewsWire January 24, 2020

Takeda Named Global Top 100 Most Sustainable Corporation for Fifth Year Running

Business Wire January 21, 2020

Takeda to Outline Progress on Business Transformation and Priorities at the 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 14, 2020

Takeda Partners with MiTest Health to Launch Innovative Disease Risk Prediction Tool to Redefine Crohn's Disease Management

PR Newswire December 13, 2019

Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting

Business Wire December 9, 2019